Literature DB >> 30476536

An integrated serum and urinary metabonomic research of Rhizoma Curcumae-Rhizoma Sparganii drug pair in hysteromyoma rats based on UPLC-Q-TOF-MS analysis.

Wenjing Li1, Bo Hong2, Qing Li3, Zuojing Li3, Kaishun Bi4.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Rhizoma Curcumae and Rhizoma Sparganii (RCRS), a celebrated traditional Chinese medicine drug pair, has been used to treat hysteromyoma (HY). AIM OF THE STUDY: We aimed to identify the endogenous biomarkers of RCRS against HY.
MATERIALS AND METHODS: HY rat model was established by injecting intramuscularly estradiol benzoate and progesterone injection from inner thigh in sequence. Body weight, uterus morphological indexes, immunohistochemistry (IHC) and hematoxylin and eosin (HE) staining experiments were used to evaluate the efficacy of RCRS (The rats were treated with RCRS extract, which was made by soxhlet reflux method. The rats were administrated intragastrically with 2 mL of RCRS extract). UPLC-Q-TOF-MS based metabonomics was adopted to analyze the serum and urine biomarkers from HY rats before and after RCRS treatment. Principle component analysis (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA) were utilized to identify differences of metabolic profiles in rats among the four groups.
RESULTS: 16 potential biomarkers from serum and 18 potential biomarkers from urine in both positive and negative mass spectrometry detection modes were identified, primarily related to Linoleic acid metabolism and Glyoxylate and dicarboxylate metabolism. RCRS drug pair has therapeutic effects on rats with HY via the regulation of multiple metabolic pathways.
CONCLUSIONS: This study provides a useful method to get insight into the integrated metabonomic mechanism of RCRS drug pair on HY rats.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hysteromyoma; Metabonomics; Rhizoma Curcumae - Rhizoma Sparganii drug pair; UPLC-Q-TOF-MS

Mesh:

Substances:

Year:  2018        PMID: 30476536     DOI: 10.1016/j.jep.2018.11.033

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  6 in total

1.  Dose Optimization of Anxiolytic Compounds Group in Valeriana jatamansi Jones and Mechanism Exploration by Integrating Network Pharmacology and Metabolomics Analysis.

Authors:  Chengbowen Zhao; Xiaojia Wei; Jianyou Guo; Yongsheng Ding; Jing Luo; Xue Yang; Jiayuan Li; Guohui Wan; Jiahe Yu; Jinli Shi
Journal:  Brain Sci       Date:  2022-04-30

2.  Inhibition of Fibroblast Activation in Uterine Leiomyoma by Components of Rhizoma Curcumae and Rhizoma Sparganii.

Authors:  Yewen Feng; Yumin Zhao; Yao Li; Teng Peng; Yu Kuang; Xingming Shi; Gang Wang; Fu Peng; Chenghao Yu
Journal:  Front Public Health       Date:  2021-03-01

3.  Chemical profiling of root bark extract from Oplopanax elatus and its in vitro biotransformation by human intestinal microbiota.

Authors:  Jin-Yi Wan; Jing-Xuan Wan; Shilei Wang; Xiaolu Wang; Wenqian Guo; Han Ma; Yuqi Wu; Chong-Zhi Wang; Lian-Wen Qi; Ping Li; Haiqiang Yao; Chun-Su Yuan
Journal:  PeerJ       Date:  2021-11-24       Impact factor: 2.984

4.  The Effect of Simvastatin on Gut Microbiota and Lipid Metabolism in Hyperlipidemic Rats Induced by a High-Fat Diet.

Authors:  Qing Zhang; Xiaoyun Fan; Rui Ye; Yuzhong Hu; Tingting Zheng; Rui Shi; Wenjian Cheng; Xucong Lv; Lijiao Chen; Peng Liang
Journal:  Front Pharmacol       Date:  2020-04-29       Impact factor: 5.810

5.  Efficiency of Sophora flavescens-Fructus Ligustri Lucidi Drug Pairs in the Treatment of Liver Fibrosis Based on the Response Surface Method.

Authors:  Shuhan Chu; Hongxu Zhang; Lixin Ding
Journal:  Evid Based Complement Alternat Med       Date:  2019-04-01       Impact factor: 2.629

6.  Modular Characteristics and Mechanism of Action of Herbs for Endometriosis Treatment in Chinese Medicine: A Data Mining and Network Pharmacology-Based Identification.

Authors:  Weilin Zheng; Jiayi Wu; Jiangyong Gu; Heng Weng; Jie Wang; Tao Wang; Xuefang Liang; Lixing Cao
Journal:  Front Pharmacol       Date:  2020-03-06       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.